Epileptic seizure

Cenobamate Designated Promising Innovative Medicine (PIM) by the UK’s MHRA for Treatment of Drug-Resistant Focal-Onset Seizures in Adults

Tuesday, August 11, 2020 - 5:00am

Commenting on the announcement, Stuart Mulheron, General Manager UK & Ireland, Arvelle Therapeutics said: The MHRA PIM designation marks an important milestone for Arvelle.

Key Points: 
  • Commenting on the announcement, Stuart Mulheron, General Manager UK & Ireland, Arvelle Therapeutics said: The MHRA PIM designation marks an important milestone for Arvelle.
  • To date, cenobamate has been approved by the US Food and Drug Administration (FDA) for the treatment of partial-onset (focal) seizures in adults, and is commercially available in the U.S.
  • In March 2020, Arvelle announced the European Medicines Agencys (EMA) acceptance of the marketing authorization application (MAA) for cenobamate for the adjunctive treatment of focal-onset seizures in adults with epilepsy.
  • Cenobamate was discovered by SK Biopharmaceuticals and SK life science and is a new FDA-approved anti-seizure medication (ASM) for the treatment of partial-onset seizures in adults (also known as focal-onset seizures).

Methodist University Hospital Is First In The World To Participate In Groundbreaking EEG Study For Inpatients That Improves Brain Monitoring During the COVID-19 Crisis

Tuesday, August 4, 2020 - 11:00am

MEMPHIS, Tenn., Aug. 4, 2020 /PRNewswire/ -- Methodist Le Bonheur Healthcare (MLH) is the first hospital system globally to participate in a landmark study using a first-of-its-kind EEG device.

Key Points: 
  • MEMPHIS, Tenn., Aug. 4, 2020 /PRNewswire/ -- Methodist Le Bonheur Healthcare (MLH) is the first hospital system globally to participate in a landmark study using a first-of-its-kind EEG device.
  • EEG tests are conducted to detect problems in the brain that may be associated with certain brain disorders such as seizures, tumors or strokes.
  • A typical EEG test consists of multiple electrodes attached to a patient's scalp with adhesive.
  • An EEG technician at Methodist University can now be more productive and perform more EEGs in a day.

Tuberous Sclerosis Alliance Lauds FDA Approval of Epidiolex® to Treat Seizures in People with Tuberous Sclerosis Complex

Saturday, August 1, 2020 - 2:43am

SILVER SPRING, Md., July 31, 2020 /PRNewswire/ --Today, the Tuberous Sclerosis Alliance (TS Alliance) lauds the U.S. Food and Drug Administration's (FDA's) approval of Epidiolex oral solution to treat seizures in people one year of age and older who have tuberous sclerosis complex (TSC).

Key Points: 
  • SILVER SPRING, Md., July 31, 2020 /PRNewswire/ --Today, the Tuberous Sclerosis Alliance (TS Alliance) lauds the U.S. Food and Drug Administration's (FDA's) approval of Epidiolex oral solution to treat seizures in people one year of age and older who have tuberous sclerosis complex (TSC).
  • "Up to 85 percent of those affected by TSC experience seizures at some point in their lifetime," explained TS Alliance President & CEO Kari Luther Rosbeck.
  • In 2018, the FDA approved the drug to treat people two years of age and older with Lennox-Gastaut syndrome (LGS) or Dravet syndrome.
  • Established in 1974, the Tuberous Sclerosis Alliance is an internationally recognized nonprofit organization dedicated to finding a cure for tuberous sclerosis complex while improving the lives of those affected.

Epilepsy Foundation is Challenging People to Wear Purple Lipstick on National Lipstick Day to Create Awareness about Epilepsy

Wednesday, July 29, 2020 - 12:30pm

LANDOVER, Md., July 29, 2020 /PRNewswire/ --To coincide with National Lipstick Day on July 29, the Epilepsy Foundation launched the #PurpleLipstickChallenge encouraging people to wear purple lipstick to bring awareness to epilepsy and seizures.

Key Points: 
  • LANDOVER, Md., July 29, 2020 /PRNewswire/ --To coincide with National Lipstick Day on July 29, the Epilepsy Foundation launched the #PurpleLipstickChallenge encouraging people to wear purple lipstick to bring awareness to epilepsy and seizures.
  • "In addition to raising funds, we want to create awareness about this brain disorder that can affect any of us.
  • We are challenging everyone to raise money for a good cause, including men because newsflash, us men can wear lipstick too!"
  • Based in Denver, CO, Kenzie started her charitable foundation, Fly 4 A Purpose , in support of epilepsy awareness and advancement.

Zogenix to Release Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 5

Wednesday, July 29, 2020 - 1:00pm

Zogenixis a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.

Key Points: 
  • Zogenixis a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
  • The companys first rare disease therapy, FINTEPLA(fenfluramine) oral solution, C-IV has been approved by theU.S.FDA and is under review inEuropefor the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy.
  • In addition, the company has two late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, a rare childhood-onset epilepsy and one for MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder.
  • MT1621 is being developed through Modis Therapeutics, aZogenixcompany.

New Published Data Show NeuroPace’s RNS® System Provides Patients with Unprecedented Seizure Reduction and Improved Quality of Life

Monday, July 27, 2020 - 1:00pm

The RNS System has been shown to dramatically reduce seizures and improve quality of life for people living with refractory epilepsy.

Key Points: 
  • The RNS System has been shown to dramatically reduce seizures and improve quality of life for people living with refractory epilepsy.
  • Real-world data from a multicenter clinical study of the RNS System were published in Epilepsia, demonstrating seizure reductions not seen with any other neuromodulation system for refractory focal epilepsy.
  • At three or more years, patients experienced an unprecedented 82% median reduction in seizure frequencythe highest reported for any neuromodulation system.
  • Physicians reported that 75% of patients who received the RNS System were much improved or very much improved in their functioning at most recent follow up.

Smart Monitor Awarded U.S. Patent for Systems to Detect Motion Disorders, Including Seizures and Epilepsy

Monday, July 20, 2020 - 5:00pm

SAN JOSE, Calif., July 20, 2020 /PRNewswire-PRWeb/ --Smart Monitor, the leading provider of clinically validated solutions for managing epilepsy and other chronic conditions, announced that the United States Patent and Trademark Office awarded United States Patent Number 10,595,766, entitled"Abnormal Motion Detector and Monitor," to Smart Monitor ('766 Patent).

Key Points: 
  • SAN JOSE, Calif., July 20, 2020 /PRNewswire-PRWeb/ --Smart Monitor, the leading provider of clinically validated solutions for managing epilepsy and other chronic conditions, announced that the United States Patent and Trademark Office awarded United States Patent Number 10,595,766, entitled"Abnormal Motion Detector and Monitor," to Smart Monitor ('766 Patent).
  • The '766 Patent covers technology for detecting motion related disorders, including seizures and epilepsy.
  • The '766 Patent belongs to a family of patents that includes United States Patent Number 8,075,499 of Smart Monitor.
  • This patent family concerns Smart Monitor's proprietary technology for providing intelligent detection, monitoring, and alerting of seizures and other conditions.

FDA Approves FINTEPLA® (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome

Friday, June 26, 2020 - 4:05am

About FINTEPLA (fenfluramine) oral solution, CIV

Key Points: 
  • About FINTEPLA (fenfluramine) oral solution, CIV
    FINTEPLA is an approved treatment, in the U.S., for seizures associated with Dravet syndrome in patients 2 years of age and older.
  • Across multiple clinical studies, FINTEPLA demonstrated significant and sustained reduction of convulsive seizures associated with Dravet syndrome.
  • If serotonin syndrome is suspected, treatment with FINTEPLA should be stopped immediately and symptomatic treatment should be started.
  • The company's first rare disease therapy, FINTEPLA (fenfluramine) oral solution, C-IV has been approved by the U.S. FDA and is under review in Europe for the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy.

FDA Approves FINTEPLA® (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome

Friday, June 26, 2020 - 1:49am

Dravet syndrome is a rare childhood-onset epilepsy marked by frequent debilitating seizures, lifelong developmental and motor impairments, and an increased risk of sudden death.

Key Points: 
  • Dravet syndrome is a rare childhood-onset epilepsy marked by frequent debilitating seizures, lifelong developmental and motor impairments, and an increased risk of sudden death.
  • About FINTEPLA (fenfluramine) oral solution, CIV
    FINTEPLA is an approved treatment, in the U.S., for seizures associated with Dravet syndrome in patients 2 years of age and older.
  • Across multiple clinical studies, FINTEPLA demonstrated significant and sustained reduction of convulsive seizures associated with Dravet syndrome.
  • If serotonin syndrome is suspected, treatment with FINTEPLA should be stopped immediately and symptomatic treatment should be started.

FDA Approves New Therapy for Dravet Syndrome

Friday, June 26, 2020 - 12:50am

Dravet syndrome is a life-threatening, rare and chronic form of epilepsy.

Key Points: 
  • Dravet syndrome is a life-threatening, rare and chronic form of epilepsy.
  • "Fintepla offers an additional effective treatment option for the treatment of seizures associated with Dravet syndrome.
  • The FDA will continue to work with companies on drug development for Dravet syndrome and other types of epilepsy."
  • The effectiveness of Fintepla for the treatment of seizures associated with Dravet syndrome was demonstrated in two clinical studies in 202subjects between ages 2 and 18.